17 October 2014

ATL1103 for Acromegaly and ATL1102 for MS

Antisense Therapeutics Limited ("ANP" or "the Company") wishes to advise that new additional data on ATL1103's activity in the disease acromegaly including those relating to its effects on signs and symptoms of acromegaly, reducing ring finger size and on quality of life assessments, will be included in a presentation on the Company's successful Phase II clinical trial of ATL1103 at the 7th International Congress of the GRS and IGF-I Society in Singapore on 18 October 2014 by Professor Peter Trainer, Chief Investigator of the trial.

Professor Trainer will also cover this new data in a presentation to shareholders and investors in Melbourne on Monday 20 October 2014 and Sydney 21 October 2014.

Investors who wish to attend will need to register their attendance by contacting Annabel Murphy at **amurphy@buchanwe.com.au** or on (02) 9237 2800.

*Please note the Melbourne and Sydney presentation will be lodged with the ASX prior to market opening on Monday 20 October 2014 and the webcast of the presentation will be accessible from the Company's website homepage on Tuesday 21 October 2014 by 12.00pm.

ATL1102 for MS

The Company would like to confirm that as previously advised, it expects to receive on October 17, 2014 (US time)/October 18 (AUS time), the US Food and Drug Administration's (FDA) written response to the Company's formal request for a Pre-Investigational New Drug assessment of ANP's plans for further clinical development of ATL1102 to treat multiple sclerosis (MS). Following receipt of the FDA's response the Company expects to make an ASX announcement in the week commencing 20 October 2014.

Contact Information:
Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (3) 9827 8999
Investor Relations: Annabel Murphy, Buchan Consulting +61 (2) 9237 2800

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 5 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with multiple sclerosis, ATL1103 a second-generation antisense drug designed to block GHr production and thereby lower blood IGF-I levels and is in clinical development as a potential treatment for growth and other GH-IGF-I disorders, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.